Caplin Point's margin improves, but stock drops 5.77%
Costs stayed aligned with revenue year on year, but a higher tax rate and other income equal to 14.31% of pre-tax profit moderated earnings growth.
Filed 12 Nov 2026, 13:07 IST · Caplin Point Laboratories Ltd (CAPLIPOINT)
Key takeaways
- Consolidated revenue grew 17.94% year on year to Rs 629.84 cr, while net profit rose a slower 13.81% to Rs 182.35 cr.
- Operating margin expanded 0.46 percentage points sequentially to 35.44% as expenses grew slower than revenue.
- The stock fell 5.77% after the results, versus a 4.38% median absolute move across its last eight result reactions.
Price around the results
Revenue growth outpaced profit growth
Caplin Point reported consolidated revenue growth of 17.94% year on year, with expenses rising almost in line at 17.91%. Operating profit therefore grew 18.00%, but profit before tax increased 15.84% and net profit 13.81% as the tax rate rose to 21.68% from 20.28%. Sequentially, revenue grew 3.19% and net profit 1.82%.
Margin improves, with other income still material
Operating margin widened 0.46 percentage points sequentially because expenses grew 2.45%, slower than the 3.19% rise in revenue. Year on year, the margin was broadly unchanged, improving just 0.02 percentage points as revenue and expenses grew at similar rates. Other income contributed 14.31% of pre-tax profit, making reported earnings less purely operating in nature.
Third straight quarter of sequential margin expansion
Operating margin has risen from 34.03% in Q4FY26 to 34.98% in Q1FY27 and 35.44% in Q2FY27, marking three consecutive quarters of improvement. The company's margin was 13.76 percentage points above the 21.68% median for 94 healthcare peers that had reported the quarter.
Management points to new products and capacity
Management said the company began commercial oncology sales in Mexico, received four product approvals during the quarter and supplied the first commercial product from its Vizag API unit to the parent company. It said Caplin Point plans to file 60+ products in non-US regulated markets over the next 18 months and launch 10 additional US products in FY28. Management also said it has allocated about Rs 1,000+ cr to investment projects, with around 50% nearing completion, while the Pondicherry facility is intended to more than double existing capacities.
Results-day decline was larger than Caplin's usual move
The stock fell 5.77% on the results day, while the stock's last eight results reactions were evenly split between four rises and four falls. The decline was larger than the 4.38% median absolute move in that history, making the reaction somewhat more pronounced than usual for the stock.
Q2FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q2FY27 | Q1FY27 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹630 cr | ₹610 cr | +3.19% | +17.94% |
| Other income | ₹33 cr | ₹34 cr | -0.66% | +9.64% |
| Expenses | ₹407 cr | ₹397 cr | +2.45% | +17.91% |
| Operating profit | ₹223 cr | ₹213 cr | +4.56% | +18.00% |
| Operating margin (%) | 35.44% | 34.98% | — | — |
| Interest | ₹0 cr | ₹0 cr | +22.22% | +37.50% |
| Depreciation | ₹23 cr | ₹22 cr | +8.65% | +27.66% |
| Profit before tax | ₹233 cr | ₹225 cr | +3.38% | +15.84% |
| Tax | ₹50 cr | ₹46 cr | +9.43% | +23.82% |
| Net profit | ₹182 cr | ₹179 cr | +1.82% | +13.81% |
| EPS (₹) | ₹23.44 | ₹23.27 | +0.73% | +15.35% |
Operating margin of 35.44% compares with a Healthcare sector median of 21.68% across 94 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -5.77% | -5.94% |
Volume on the results session was 5.39× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company began commercial sales of oncology products in Mexico and received four new product approvals during the quarter.
- The Vizag general API unit received its commercial licence and supplied its first commercial product to the parent company.
Guidance & outlook
- The company plans to file 60+ products in non-US regulated markets over the next 18 months, with meaningful revenue expected in FY27 and FY28.
- The company plans to launch 10 additional products in the US in FY28.
- First DMFs from the Thervoy oncology API plant are expected in the year after its CY27 completion.
- Amaris Clinical expansion is expected to increase capacity to 120 beds by the end of FY27.
Expansion
- The company allocated approximately ₹1,000+ crore for investment projects, with about 50% nearing completion and completion expected over two years.
- The investment projects are expected to be fully commercialised within one year of completing the investments.
- The Pondicherry OSD and Dermatology facility is intended to more than double existing capacities and support regulated-market entry.
New orders
- The company won Central America tenders worth $5.3 million, to be supplied over the next three quarters.
- The company won Chile tenders worth $5 million, to be supplied over the next 18 months.
New products
- The company completed exhibit batches for two pre-filled syringe products and has 12 more under active development for FY28 filing.
New initiatives
- The company has started expanding Amaris Clinical to meet additional demand from internal pipeline products.
- Multiple OSD and softgel products from the internal R&D pipeline recently completed pivotal bioequivalence studies.
What to watch
- Whether operating margin holds above 35.44% in the next quarter.
- Whether the tax rate moves back from 21.68% after its year-on-year increase.
- Progress on management's stated plan to file 60+ products in non-US regulated markets over the next 18 months.